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Background: The effects of dexmedetomidine on the propofol-sparing effect and intraoperative hemodynamics 
during remifentanil-based propofol-supplemented anesthesia have not been well investigated.
Methods: Twenty patients undergoing breast surgery were randomly allocated to receive dexmedetomidine (group 
DEX) or placebo (group C). In the DEX group, dexmedetomidine was loaded (1 μg/kg) before anesthesia induction 
and was infused (0.6 μg/kg/h) during surgery. Anesthesia was induced with a target-controlled infusion (TCI) of 
propofol (effect site concentration, Ce; 3 μg/ml) and remifentanil (plasma concentration, Cp, 10 ng/ml). The Ce of 
TCI-propofol was adjusted to a bispectral index of 45-55, and Cp of TCI-remifentanil was fixed at 10 ng/ml in both 
groups. Mean arterial blood pressure (MAP) and heart rate (HR) were recorded at baseline (T-control), after the 
loading of study drugs (T-loading), 3 min after anesthesia induction (T-induction), tracheal intubation (T-trachea), 
incision (T-incision), 30 min after incision (T-incision30), and at tracheal extubation (T-extubation). MAP% and HR% 
(MAP and HR vs. T-control) were determined and the propofol infusion rate was calculated.
Results: The propofol infusion rate was significantly lower in the DEX group than in group C (63.9 ± 16.2 vs. 96.4 ± 
10.0 μg/kg/min, respectively; P < 0.001). The changes in MAP% at T-induction, T-trachea and T-incision in group 
DEX (-10.0 ± 3.9%, -9.4 ± 4.6% and -11.2 ± 6.3%, respectively) were significantly less than those in group C (-27.6 
± 13.9%, -21.7 ± 17.1%, and -25.1 ± 14.1%; P < 0.05, respectively). 
Conclusions: Dexmedetomidine reduced the propofol requirement for remifentanil-based anesthesia while 
producing more stable intraoperative hemodynamics. (Korean J Anesthesiol 2012; 62: 113-118)
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Introduction
Dexmedetomidine (DEX), a highly selective α2-adrenore-
ceptor agonist, is used for sedation management in various 
clinical settings and shows an anesthetic-sparing effect [1-5]. 
DEX reduces the propofol requirement in remifentanil-based 
anesthesia for faster postoperative recovery and more stable 
intraoperative hemodynamics [6-8], but the possible propofol-
sparing effect during remifentanil-based anesthesia has not 
been well investigated. 
DEX has complex vasodilative and vasoconstrictive hemo-
dynamic effects specific to its activation of pre- and post-
synaptic α2-receptors. These effects are dose-dependent and 
biphasic: vasodilation at lower dosages, vasoconstriction at 
higher dosages and an initial short-term increase in blood 
pressure (BP) followed by a longer lasting reduction in BP 
and heart rate (HR). Several investigations have identified the 
cardiovascular effects of DEX in various clinical settings [1,9-11], 
however its effect on intraoperative hemodynamics during 
a propofol-supplemented remifentanil-based anesthesia 
regimen, which produces a strong vasodilatory effect, has not 
been investigated. 
We conducted this study to determine whether DEX affects 
the requirement for propofol and to describe the intraoperative 
hemodynamics during remifentanil-based propofol-supple-
mented anesthesia for breast surgery.
Materials and Methods
Study population
After obtaining approval from the institutional review 
board and written informed consent from all patients, only 
American Society of Anesthesiologists physical status I female 
patients undergoing elective breast surgery were prospectively 
investigated. 
Patient exclusion criteria were: 1) patient age < 18 or > 80 
years, 2) preoperative hypotension (Mean arterial blood 
pressure < 60 mmHg), 3) preoperative bradycardia (Heart rate 
< 45 beats/min), and 4) preoperative dysrrhythmia.
Using the sealed envelope method, 20 patients were 
randomly allocated into a DEX group (n = 10) or normal saline 
group (placebo, group C, n = 10) before anesthesia induction. 
Study drugs (DEX or normal saline) in 50 ml syringes were 
prepared by a pharmacist and anesthesiologists were blinded to 
the syringe contents. 
Anesthetic regimens and study drug administration 
Invasive arterial BP monitoring in the radial artery contra-
lateral to the surgical site and routine non-invasive patient 
monitoring, including pulse oximetry, electrocardiography 
and bispectral index (BIS) were established upon the patient’s 
arrival in the operating room. In group DEX, DEX (1 μg/kg) was 
loaded intravenously for 10 min before anesthesia induction 
and was continuously infused at 0.6 μg/kg/h until the end of 
surgery. The same volume of normal saline was administered in 
the same manner to group C. 
After the intravenous administration of 0.075 mg of palo-
nosetron, a target-controlled infusion (TCI) of propofol with 
an effect-site concentration (Ce) of 3 μg/ml and a TCI of remi-
fentanil with a plasma concentration (Cp) of 10 ng/ml were 
started to induce anesthesia. Bolus rocuronium (0.6 mg/kg) was 
administered to facilitate tracheal intubation in both groups. 
After tracheal intubation, volume-controlled ventilation with an 
air/O2 mixture (FiO2, 0.3-0.4) was followed with a tidal volume 
of 7 ml/ideal body weight and a respiratory rate to maintain 
end-tidal CO2 (EtCO2) at 35-40 mmHg with an I : E ratio of 
1 : 2. The Cp of TCI-remifentanil was fixed at 10 ng/ml, and 
the Ce of TCI-propofol was reduced to the minimum dosage 
needed to maintain a BIS of 45-55. Additional rocuronium (0.1 
mg/kg) was administered under the guidance of peripheral 
neuromuscular monitoring in both groups.
Intravenous phenylnephrine (50-100 μg) was administered 
if MAP dropped to < 60 mmHg. A HR of < 45 beats/min was 
treated with intravenous administration of 0.2 mg of glycopy-
rrolate or 0.5 mg of atropine. Patients who were administered 
atropine were excluded from the study.
During suturing of the subcutaneous tissue at the operation 
site, 1.0 μg/kg of fentanyl and 30 mg of ketorolac were 
administered intravenously and the anesthetics were stopped. 
Tracheal extubation was performed after confirming sufficient 
recovery (TOF ratio > 95%; BIS > 80, ability to open the eyes, 
ability to obey anesthesiologist’s verbal commands and ability 
to maintain a regular breathing pattern) and patients were then 
transferred to a post-anesthesia care unit. 
Data measurements 
Operation time, extubation time (the time from stopping 
the administration of anesthetic agents to tracheal extubation) 
and the total volume of intraoperative intravascular fluids 
administered were recorded. The total doses of remifentanil, 
propofol and DEX were recorded, and their mean infusion rates 
were calculated. 
To stabilize the patients’ vital signs, monitoring was per-
formed 5 min after arrival in operation theater. MAP and HR 
were then measured after the 5 min (T-control), after the 
loading of the study drugs (T-loading), 3 min after the start 
of TCI-propofol and remifentanil (T-induction), at tracheal 115 www.ekja.org
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intubation (T-trachea), at surgical incision (T-incision), at 
30 min after surgical incision (T-incision30) and at tracheal 
extubation (T-extubation). The lowest values of MAP and 
HR for a 3 min observation were recorded as baseline values 
at T-control and the MAP and HR values with the greatest 
deviation from baseline during 3 min observations at T-trachea, 
T-incision, T-incision30 and T-extubation were recorded. 
The percentile data (%) of these values versus T-control 
values and the changes in MAP% and HR% at each time point 
from those at T-control (ΔMAP% and ΔHR%) were determined. 
Statistical analysis
A sample size of 10 in each group was determined to be 
appropriate for identifying a 15% difference with a power of 
0.8 and an α value of 0.05, for a mean propofol infusion rate of 
96.6 ± 10.6 μg/kg/min, which was determined in nine volunteer 
patients in a preliminary study. 
Inter-group differences in the data collected at each 
meas  ured time point were determined using a t-test (student 
t-test) and intra-group differences in MAP and HR in each 
group were determined by a Friedman test. Sigmastat ver.3.1 
(Systat Software Inc, San Jose, CA, USA) was used for all 
statistical analyses and P < 0.05 was considered to indicate 
statistical significance.
Results
The patient demographic profiles, operation time and 
volume of intravascular fluids administered were not signi-
ficantly different between the two groups (Table 1). 
No patient in either group required bolus phenylephrine, 
ephedrine, atropine or glycopyrrolate.
The mean infusion rate of propofol in group DEX was 
significant lower than that in group C (63.9 ± 16.2 vs. 96.4 ± 
10.0 μg/kg/min, respectively; P < 0.001) (Fig. 1). The mean 
remifentanil infusion rate did not significantly differ between 
the two groups (0.367 ± 0.045 μg/kg/min in group C vs. 0.379 ± 
0.051 μg/kg/min in the group DEX, P = 0.57). 
MAP and HR at T-control were not significantly different bet-
ween the groups (Table 2). The MAPs at T-induction, T-incision, 
T-incison30 and T-extubation were significantly lower than that 
at T-control in group DEX (p < 0.05: Table 3). In group C, the 
MAPs at T-induction, T-incision, T-incision30 were significantly 
lower than that at T-control (Table 3). The MAPs at T-induction, 
T-trachea, T-incision, T-incison30 and T-extubation in group 
DEX were significantly higher than those in group C (P < 0.001, 
P < 0.001, P = 0.001, P = 0.004, and P = 0.002, respectively: Table 2).
Table 2. Inter-group Comparisons in Mean Arterial Pressure and Heart Rate
Parameter Group T-control T-loading T-induction T-trachea T-incision T-incison30 T-extubation
MAP (mmHg)
HR (beats/min)
Group C
Group DEX
Group C
Group DEX
99.9 ± 20.6
97.0 ± 6.5
72.9 ± 15.3
74.5 ± 20.4
100.0 ±18.9
104.8 ± 7.2
71.7 ± 11.3
58.1 ± 8.7*
71.0 ± 11.1
87.2 ± 5.8*
62.3 ±13.9
57.1 ± 10.5
75.3 ± 7.1
87.8 ± 6.5*
65.6 ± 17.3
58.5 ± 10.3
72.9 ± 10.3
86.0 ± 6.3*
55.9 ± 9.4
57.0 ± 7.8
73.3 ± 5.8
84.4 ± 8.8*
56.7 ± 8.5
53.7 ± 5.7
74.1 ± 6.9
83.9 ± 5.3*
60.3 ± 9.5
60.2 ± 7.5
The values are expressed as means ± SD. P values determined by a t-test. Group C: remifentanil-propofol, Group DEX: remifentanil-propofol-
dexmedetomidine, MAP: mean arterial blood pressure, HR: heart rate, T-control: at the arrival to operation theater, T-loading: at after the 
loading of study drugs, T-induction: at 3 min after the start of anesthesia induction, T-trachea: at tracheal intubation, T-incision: at surgical 
incision, T-incision30: at 30 min after surgical incision, T-extubation: at tracheal extubation. *Indicates P < 0.05 vs. Group C at each measured 
time point.
Table 1. Demographic Data and Perioperative Parameters
Parameter
Group C  
(n = 10)
Group DEX  
(n = 10)
P value
Age (yr)
Height (cm)
Weight (kg)
BSA (m
2)
OP time (min)
Intraop IV fluid (ml)
49 ± 10
162 ± 6
59.9 ± 5.8
1.65 ± 0.11
135 ± 26
533 ± 189
52 ± 11
156 ± 7
55.7 ± 5.6
1.56 ± 0.10
123 ± 16
467 ± 135
0.55
0.06
0.11
0.07
0.21
0.35
The values are expressed as means ± SD. P values determined by a 
t-test. C: remifentanil-propofol, DEX: remifentanil-propofol-dexme-
detomidine, BSA: body surface area, OP time: operation duration, 
Intraop: intraoperative, IV: intravenous.
Fig. 1. Inter-group comparison of supplemental propofol require-
ments. C: remifentanil-propofol, DEX: remifentanil-propofol-dex-
medetomidine. *Indicates P < 0.05 vs. group C.116 www.ekja.org
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The ΔMAP% values at T-induction, T-trachea, and T-incision 
were significantly less in group DEX (-10.0 ± 3.9%, -9.4 ± 4.6% 
and -11.2 ± 6.3%, respectively) than in group C (-27.6 ± 13.9%, 
-21.7 ± 17.1% and -25.1 ± 14.1%; P = 0.001, P = 0.042, and P = 
0.011, respectively). The ΔMAP% at T-loading was significantly 
greater in group DEX (8.3 ± 7.5%) than in group C (0.5 ± 3.6%; P 
= 0.001: Fig. 2).
The HRs at T-induction, T-incision and T-incison30 were 
significantly lower than that at T-control in group DEX (P < 0.05), 
and the HRs at T-incision and T-incision30 were significantly 
lower than that at T-control in group C (P < 0.05: Table 3). HR 
at T-loading in group DEX was significantly lower than that in 
group C (P = 0.008: Table 2). 
The ΔHR at T-loading in group DEX (-19.2 ± 13.5%) was 
significantly greater than that in group C (-0.8 ± 5.2%; P < 0.05: 
Fig. 2). 
The extubation time did not differ between the groups (11 ± 
4 min in group C vs. 9 ± 3 min in group DEX, P = 0.41).
Discussion
We evaluated the effect of DEX on the requirement for 
supple  mental propofol and described the intraoperative hemo-
dynamic changes during remifentanil-based anesthesia. DEX 
reduced the amount of adjuvant propofol needed to maintain 
a similar BIS score by approximately 30% and provided more 
stable hemodynamics without compromising postoperative 
recovery during remifentanil-based anesthesia. These results 
are consistent with previous investigations showing a 30-50% 
reduction in the propofol requirement with concomitant use 
of DEX in adolescent patients and healthy volunteers [2,3]. The 
sedative effect of DEX is mediated through the locus ceruleus 
Table 3. Intra-group Comparisons in Mean Arterial Pressure and Heart Rate
Parameter Group T-control T-loading T-induction T-trachea T-incision T-incison30 T-extubation
MAP (mmHg)
HR (beats/min)
Group C
Group DEX
Group C
Group DEX
99.5 
(91.0-111.0)
96.5 
(93.0-100.0)
70.5 
(64.0-78.0)
65.5 
(64.0-96.0)
98.0 
(90.0-108.0)
102.5 
(100.0-112.0)
69.5 
(65.0-75.0)
57.5 
(50.0-66.0)
70.0 
  (62.0-79.0)*
88.0 
  (83.0-91.0)*
56.0 
(54.0-74.0)
58.5 
  (48.0-66.0)*
75.0 
(71.0-80.0)
89.0 
(84.0-92.0)
65.5 
(55.0-67.0)
57.0 
(50.0-70.0)
72.0 
  (63.0-76.0)*
87.0 
  (79.0-89.0)*
56.0 
  (48.0-63.0)*
57.5 
  (52.0-63.0)*
73.0 
(70.0-79.0)*
84.5 
(82.0-87.0)*
56.0 
(48.0-63.0)*
53.5 
(50.0-58.0)*
72.0 
(70.0-80.0)
82.0 
  (80.0-88.0)*
62.5 
(52.0-68.0)
59.5 
(55.0-64.0)
The values are expressed as median and range (25-75%) and significance was determined by a Friedman	test. Group C: remifentanil-propofol, 
Group DEX: remifentanil-propofol-dexmedetomidine, MAP: mean arterial blood pressure, HR: heart rate, T-control: at the arrival to operation 
theater, T-loading: at after the loading of study drugs, T-induction: at 3 min after the start of anesthesia induction, T-trachea: at tracheal 
intubation, T-incision: at surgical incision, T-incision30: at 30 min after surgical incision, T-extubation: at tracheal extubation. *Indicates P < 0.05 
vs. T-control in the same group.
Fig. 2. Inter-group comparisons of the changes in mean arterial blood pressure and heart rate compared with control values (ΔMAP% and 
ΔHR%). C: remifentanil-propofol, DEX: remifentanil-propofol-dexmedetomidine, MAP: mean arterial blood pressure, HR: heart rate, 
T-control: at the arrival to operation theater, T-loading: at after the loading of study drugs, T-induction: at 3 min after the start of anesthesia 
induction, T-trachea: at tracheal intubation, T-incision: at surgical incision, T-incision30: at 30 min after surgical incision, T-extubation: at 
tracheal extubation. *Indicates P < 0.05 vs. group C.117 www.ekja.org
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in the brain stem, where DEX decreases sympathetic outflow 
and increases parasympathetic outflow [4,12-14]. The different 
mechanisms for producing a sedative effect among DEX, 
propofol and remifentanil suggest a possible synergism upon 
combined administration with respect to their sedative effects. 
Previous investigations commented on a possible delay in 
recovery from propofol anesthesia with the concomitant use of 
DEX, probably due to its quite long duration of action [3,5,11,15]. 
However, no compromises in prolongation of extubation 
time or recovery profiles were observed in the present study 
when employing remifentanil-based propofol-supplemented 
anesthesia. The reason for this result might be associated with 
Ce of propofol in the group DEX: the Ce of propofol at the end of 
surgery in group DEX (1.0-1.5 μg/ml) was relatively lower than 
that in group C (2.0-2.5 μg/ml) and it was already lower than 
the usual Ce of propofol for awakening when used alone (~1.5 
μg/ml) [16]. Therefore, although DEX might induce delayed 
recovery or awakening in the DEX group, it may be attenuated 
by the low Ce of propofol at the end of surgery.
The propofol-sparing effect of DEX may be beneficial for 
reducing the propofol dosage and avoiding adverse effects such 
as myocardial depression, metabolic acidosis, impaired platelet 
aggregation and extended recovery caused by prolonged and 
large-dose administration of propofol [17-24]. 
DEX shows complex hemodynamic effects, as it produces 
not only vasodilation by activating pre-synaptic α2-receptors 
on sympathetic and post-synaptic α2-receptors of the central 
nervous system (sympatholysis), but also vasoconstriction 
through post-synaptic α2-receptors on vascular smooth muscle 
cells [25-28]. Furthermore, the overall effect of DEX on MAP and 
HR is biphasic and dose-dependent [14,25-27], characterized 
by an initial short-term increase in BP followed by a longer 
lasting reduction in BP and HR. Lower DEX dosages (plasma 
concentrations, 0.7-1.2 ng/ml) reduce norepinephrine release, 
resulting in an attenuation of vascular and sympathetic tone and 
an inhibition of sympathetic neurotransmission by activating 
α2A receptors [9,10,12,29]. Higher DEX dosages (i.e. plasma 
concentrations, > 1.9 ng/ml) produce α2B receptor-mediated 
vasoconstriction [9,12,14]. Despite this variability, most previous 
investigations have shown the cardiovascular depressive 
effects of DEX, which increases the incidence of hypotension 
and bradycardia [1,10,11]. We had assumed that DEX would 
show a more intense depressive effect and would increase the 
need for vasoactive medication during remifentanil-based 
anesthesia. However, we observed a significant increase in MAP 
immediately after loading DEX (1 μg/kg) and a more constant 
MAP was observed during anesthesia induction, intubation and 
surgical incision. A significant reduction in MAP was observed 
in the control group. Some reasons include: first, this result was 
probably attributable to the dominant hemodynamic effect of 
DEX through postsynaptic α2B-mediated vasoconstriction at 
higher dosages [28] compared with the vasodilatory effect of 
remifentanil at the dosages used in the present study. Second, 
the reduced propofol dosage owing to adjuvant DEX might have 
contributed to less of a propofol-induced vasodilatory effect in 
group DEX. This dose-dependent vasoconstrictive effect and 
resulting aggravation of pre-existing systemic or pulmonary 
hypertension should be considered.
In conclusion, DEX (1 μg/kg loading dose and infusion at 
0.6 μg/kg/h) reduced the requirement for adjuvant propofol 
during remifentanil-based anesthesia without compromising 
the recovery profile, as indicated by extubation time. DEX also 
provided more stable intraoperative hemodynamics during 
remifentanil-based anesthesia. 
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